Elena Daniela Aflorei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elena Daniela Aflorei has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anca Neluta Dragu
Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK
1 shared publication- Benjamin Klapholz
Department of Physiology, Development, and Neuroscience, University of Cambridge, Downing Street, Cambridge CB2 1DY, UK
1 shared publication Chenghao Chen
Department of Cell and Developmental Biology, Division of Biosciences, Faculty of Life Sciences, University College London, London, UK
1 shared publication- Chrisostomos Prodromou
Department of Biochemistry and Biomedicine, University of Sussex, Brighton BN1 9QG, UK
1 shared publication - Márta Korbonits
Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , London EC1M 6BQ
1 shared publication - Nina Moderau
Department of Surgery and Cancer, Imperial College, London, UK
1 shared publication
Latest Publications
- Open Access
- 9 April 2018
- Published by BMJ in Journal of Medical Genetics
- Vol. 55 (8) , 522-529
In vivo bioassay to test the pathogenicity of missense human AIP variants
Background: Heterozygous germline loss-of-function mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to childhood-onset pituitary tumours. The pathogenicity of missense variants may pose difficulties for genetic counselling and family follow-up. Objective: To develop an in vivo system to test the pathogenicity of human AIP mutations using the fruit fly Drosophila melanogaster. Methods: We generated a null mutant of the Drosophila AIP orthologue, CG1847, a gene located on the Xchromosome, which displayed lethality at larval stage in hemizygous knockout male mutants (CG1847exon1_3 ). We tested human missense variants of ‘unknown significance’, with ‘pathogenic’ variants as positive control. Results: We found that human AIP can functionally substitute for CG1847, as heterologous overexpression of human AIP rescued male CG1847exon1_3 lethality, while a truncated version of AIP did not restore viability. Flies harbouring patient-specific missense AIP variants (p.C238Y, p.I13N, p.W73R and p.G272D) failed to rescue CG1847exon1_3 mutants, while seven variants (p.R16H, p.Q164R, p.E293V, p.A299V, p.R304Q, p.R314W and p.R325Q) showed rescue, supporting a non-pathogenic role for these latter variants corresponding to prevalence and clinical data. Conclusion: Our in vivo model represents a valuable tool to characterise putative disease-causing human AIP variants and assist the genetic counselling and management of families carrying AIP variants.
- 9 April 2018
- Published by BMJ in Journal of Medical Genetics
- Vol. 55 (8) , 522-529
Open AccessIn vivo bioassay to test the pathogenicity of missense human AIP variants
Background: Heterozygous germline loss-of-function mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP) predispose to childhood-onset pituitary tumours. The pathogenicity of missense variants may pose difficulties for genetic counselling and family follow-up. Objective: To develop an in vivo system to test the pathogenicity of human AIP mutations using the fruit fly Drosophila melanogaster. Methods: We generated a null mutant of the Drosophila AIP orthologue, CG1847, a gene located on the Xchromosome, which displayed lethality at larval stage in hemizygous knockout male mutants (CG1847exon1_3 ). We tested human missense variants of ‘unknown significance’, with ‘pathogenic’ variants as positive control. Results: We found that human AIP can functionally substitute for CG1847, as heterologous overexpression of human AIP rescued male CG1847exon1_3 lethality, while a truncated version of AIP did not restore viability. Flies harbouring patient-specific missense AIP variants (p.C238Y, p.I13N, p.W73R and p.G272D) failed to rescue CG1847exon1_3 mutants, while seven variants (p.R16H, p.Q164R, p.E293V, p.A299V, p.R304Q, p.R314W and p.R325Q) showed rescue, supporting a non-pathogenic role for these latter variants corresponding to prevalence and clinical data. Conclusion: Our in vivo model represents a valuable tool to characterise putative disease-causing human AIP variants and assist the genetic counselling and management of families carrying AIP variants.